(Prof. Alain Carpentier and his artificial heart, Reuters Photo)
Society Carmat, designer of prosthetic heart the most advanced in the world, is part Thursday with success in the conquest of the Exchange. The artificial heart should be marketed 2013.
The artificial heart Carmat society is the most successful in the world. The company announced in June its intention to make its IPO to raise funds in hopes of finalizing his research and market her prosthesis in 2013. Now it is done: Carmat has been listed Wednesday, raising a record $ 15.5 million. Its clinical trials should begin next year, provided of course the green light from the French Agency for Health Products (AFSSAPS). The bioprosthesis was implanted in six patients initially time, then with 16 others, said Patrick Coulombier, Deputy CEO of Carmat.
This little gem of technology, which weighs 900 grams, contained in identical cardiac contraction of the human heart. "Show curves to a cardiologist, he will tell you it's a human heart. Well no, it's a prosthetic!, "Says its designer, Professor Alain Carpentier, a specialist in cardiovascular surgery worldwide known for the invention of the heart valves" Carpentier-Edwards ®. It is the result of over 15 years of research, and has many advantages over what already exists.
No risk of rejection
First, it is the first fully implantable artificial heart. It is self-regulated hemocompatible: specifically, it is perfectly tolerated by the body without the risk of clots or transplant rejection, according to the release of the company. It also provides genuine autonomy for the patient: the battery of the bioprosthesis, which can be worn as straps or backpack-discharges in five to six hours, or as much time during which the graft can go about freely without having to be connected to the mains. The prosthesis has so far a lifespan of five years, which represents nearly 230 million heartbeats. Eventually, it will ensure a lifetime equivalent to that of a graft, nine years. In terms of cost, it is announced between 140,000 and 180,000 euros, slightly less than the transplant of a human heart, where it costs about 260,000 euros.
Compared to other existing cardiac devices-mostly American design-that of Carmat is the most technologically advanced. If the tests were convincing, it would be a revolution for people with heart failure. Only 4000 transplants are performed each year worldwide for some 100 000 patients waiting for transplants.
Marie Desnos - Parismatch.com
0 comments:
Post a Comment